Epigenetic therapy before prostate surgery
Part of Cancer clinical trials.
This trial tests a short course of 'epigenetic therapy' (drugs that change how genes work) given before prostate removal surgery. The goal is to see if it can improve treatment effects and help shrink or control the tumor.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be scheduled for prostate removal surgery (radical prostatectomy) and have a sample of your prostate tissue available.
- You should be in generally good health, able to handle daily activities, and have normal organ function (liver, kidneys, blood counts).
- No other active cancer or recent cancer treatments (chemotherapy, radiation, hormone therapy) in the past month.
- If you or your partner could get pregnant, you must use condoms or avoid sex during the study and for 3 months after treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a combination of hormone therapy and a targeted drug before prostate surgery for men with high-risk prostate cancer that has not spread. The goal is to see if this approach can improve outcomes.
This Phase 2 trial studies giving strong hormone-based treatment before prostate surgery to shrink and control high-risk, locally advanced prostate cancer. It may help improve surgical success and reduce cancer spread risk, but it requires careful health checks and prior-treatment limits.
This trial tests a combination of hormone therapy, a targeted pill (Darolutamide), and an immunotherapy drug (Pembrolizumab) before and after surgery for men with high-risk prostate cancer that has specific genetic features. The goal is to see if this approach helps prevent the cancer from coming back.
This trial compares two radioactive drugs (177Lu-PSMA-617 and 225Ac-PSMA-617) given before prostate removal surgery in men with high-risk prostate cancer that has not spread far. The goal is to see which drug is better at shrinking the tumor and reducing the chance of cancer coming back.
This trial tests a precise, short-course radiation treatment (stereotactic body radiotherapy) after prostate removal surgery that adapts to your body each day to reduce side effects. It is for people whose prostate cancer has high-risk features or a rising PSA after surgery.
This trial tests different drugs before prostate surgery based on a person's genetic profile. It aims to find better treatments for high-risk prostate cancer that hasn't spread yet.
Hear when a new High Risk Prostate Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.